Precision Medicine

As cancer strikes younger patients, a new partnership aims to find the disease before symptoms start. But is this new technology ready for prime time?

San Diego's Origin Health unveils a new site and opens registration for its charity golf event, funding vital healthcare for local veterans and first responders.

A novel transdermal curcumin gel shows significant pain reduction in a clinical trial, offering a potential non-oral alternative for millions with knee pain.

A breakthrough test for Parkinson's is expanding worldwide, promising earlier, more accurate diagnoses and accelerating the hunt for a cure.

Abbisko's irpagratinib gets EMA Orphan Drug status, fast-tracking a precision therapy for a hard-to-treat liver cancer subgroup with unmet needs.

China’s top infant formula maker is rewriting the global playbook, using cutting-edge research and local insight to challenge established giants in Southeast Asia.

Facing a severe cash crunch and delisting threats, the biotech firm is halting development and seeking buyers for its innovative cancer drug pipeline.

NewBeauty's 16th annual awards spotlight 395 winners, signaling a major shift towards science-backed efficacy and holistic health in the beauty market.

With its lead drug for a rare pediatric liver disease entering late-stage trials, NorthSea Therapeutics adds a veteran drug developer to its board.

A new, highly selective oral drug for the most common form of dwarfism has been cleared for U.S. trials, offering hope for a more convenient treatment.

HistoSonics begins a landmark trial for a non-invasive BPH therapy that uses focused ultrasound to mechanically destroy tissue without incisions or heat.

A new drug not only reduces osteoarthritis pain significantly but may also be the first to modify the disease itself, a landmark study in The Lancet reveals.

Amid a tough biotech market, the firm extends its cash runway to 2027, accelerating development of its promising rademikibart treatment for respiratory diseases.

NUCOT celebrates patients thriving 25+ years post-transplant, setting new global benchmarks in survival rates through advanced care and resilience.

With a fortified balance sheet and promising clinical data, Monopar Therapeutics is advancing its lead drug, ALXN1840, toward a pivotal NDA filing.

As Mochi Health takes the stage at a top women's health summit, a look behind the PR reveals a company battling rapid growth and customer complaints.

After its pivotal trial for ersodetug missed its primary endpoint, Rezolute gets a rare nod from the FDA to submit full data, igniting new hope.

A Denver clinic now offers Therapeutic Plasma Exchange for anti-aging. But does the science back up the high-cost promise of turning back the clock?

New research on ILUMYA, LEQSELVI, and WINLEVI shows sustained efficacy and faster results, aiming to transform treatment for millions of patients.

A landmark partnership is scaling a 'one-drug, many-diseases' therapy, revealing how logistics, not just labs, are key to the future of medicine.